Reports of Practical Oncology and Radiotherapy最新文献

{"title":"Evaluation of dose distributions in the overlapping regions of the modulated volumetric arcs used in total body irradiation in pediatric patients.","authors":"Eduardo Carrasco Solis, Antonella A Anticona Verástegui, J Fernando Márquez Pachas, Alberto E Gonzales-Ccoscco, Cecilia Querevalu Garcia, Yesenia Miranda Tunque, Gustavo Sarria Bardales, Carlos Herrera Castillo, Edward Artemio Meca Castro, José Santa Cruz Delgado, Fernando Carrasco, Ana P Perini, Lucio P Neves, Arthur S B Z Alves, Alessa Maschio, Jhonny Antonio Benavente Castillo, Galo Patino Camargo, William S Santos","doi":"10.5603/rpor.104734","DOIUrl":"https://doi.org/10.5603/rpor.104734","url":null,"abstract":"<p><strong>Background: </strong>The application of total body irradiation (TBI), using intensity-modulated techniques with dynamic arcs, creates overlap at the treatment arc boundaries, which can lead to dosimetric variations. Therefore, this research aimed to evaluate the dose distributions in the overlap regions of the arcs used in total body irradiation in pediatric patients.</p><p><strong>Material and methods: </strong>This dosimetric evaluation was conducted on a CIRS 715-TY0710 pediatric body simulator, where a treatment plan with three isocenters was designed, generating two 4 cm overlap regions along the line connecting the isocenters. The plan was verified using the gamma criteria of 3%/3mm and 5%/5mm with the Octavius 4D software.</p><p><strong>Results and conclusions: </strong>The planning results showed 98.2% dose coverage over 95% of the planning target volume (PTV) with adequate tolerance for risk organs. Regarding the gamma analysis, the acceptance rate was greater than 95% at the treatment isocenters with criteria of 3%/3 mm and 5%/5 mm. However, there is a decrease in the approved points in the overlap zone when evaluated with a 3%/3 mm criterion, while maintaining an approval percentage above 95% when evaluated with a 5%/5 mm criterion.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"71-78"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the beam width and profile of kilovoltage CBCT using different measurement techniques and analysis of the dosimetric effects of beam parameters.","authors":"Szilvia Gazdag-Hegyesi, Ádám Gáldi, Enikő Koszta, Gábor Stelczer, Domonkos Szegedi, Tibor Major, Csilla Pesznyák","doi":"10.5603/rpor.104733","DOIUrl":"https://doi.org/10.5603/rpor.104733","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study is to investigate the beam width and beam profile of kilovoltage cone beam computed tomography (kV CBCT) using different measurement techniques on an O-ring linear accelerator. The effect of the imaging beam on the dosimetric parameters was analysed.</p><p><strong>Materials and methods: </strong>The uncertainty of field size adjustment, the dependence of beam width on field size, and the effect of deflection from the isocenter on the beam profile were investigated by ionization chamber detector matrices. The 2D beam profile of the CBCT was analysed by relative ionization chamber measurements.</p><p><strong>Results: </strong>The average setup uncertainties of the field sizes were 0.3 mm ± 0.02 mm. The dependence of beam width on field size investigation revealed that the largest discrepancies occurred for small field sizes, which are important in determining computed tomography dose index (CTDI) values of the kV CBCT. The beam width deviation between measured and vendor-based data was larger than 1 mm below 40 mm field of view. The pelvis protocol demonstrated the smallest CTDI value difference of 2.3%, yet presented the largest effective dose deviation of 0.12 mSv.</p><p><strong>Conclusions: </strong>The measured CTDI coefficients were higher than predicted by the manufacturer for all cases. The currently internationally recommended CTDI measurement protocols for CBCT contain no reference to the determination of the beam width as a basic element of the calculations. Based on our measurement results, the beam width parameters affect CTDI: therefore, it would be advisable to apply this type of correction.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"79-87"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term aspirin use influences the probability of distant metastases and operability in patients with pancreatic ductal adenocarcinoma: a single-center retrospective study.","authors":"Aml Mustafa Banni, Milan Vošmik, Stanislav John, Filip Čečka, Libor Hruška, Miroslav Hodek, Ondřej Sobotka, Igor Sirák","doi":"10.5603/rpor.104017","DOIUrl":"https://doi.org/10.5603/rpor.104017","url":null,"abstract":"<p><strong>Background: </strong>Aspirin, a non-steroidal anti-inflammatory drug and platelet inhibitor, has been shown to reduce cancer incidence, lower metastatic rates and improve survival in certain cancer types. However, data on the effect of aspirin on prognosis in pancreatic ductal adenocarcinoma (PDAC) are limited. Therefore, we conducted a retrospective, single-center study to evaluate the impact of aspirin use on disease characteristics and survival in PDAC patients.</p><p><strong>Materials and methods: </strong>The study analyzed data from all consecutively treated PDAC patients over a 6-year period. Operability, Tumor-Node-Metastasis (TNM) stage, and survival endpoints were compared between patients who had used aspirin for 2 or more years prior to their diagnosis (ASA ≥ 2) and those who did not (ASA 0).</p><p><strong>Results: </strong>A total of 182 patients were included. In the ASA ≥ 2 group, significantly fewer patients had metastatic disease at diagnosis, and a significantly larger proportion presented in the operable stages, compared to the ASA 0 group. No significant differences were observed between the two groups in the T or N stages, overall survival, disease-free survival, or time to progression-free survival.</p><p><strong>Conclusions: </strong>Although long-term aspirin use did not influence survival endpoints, it was associated with a significantly lower probability of demonstrable distant metastases at diagnosis and a higher rate of resectable disease. This finding warrants further research to explore new therapeutic approaches for the treatment of PDAC.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"1-10"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance evaluation of MVision AI Contour+ in gastric MALT lymphoma segmentation.","authors":"Hideharu Miura, Soichiro Ishihara, Masahiro Kenjo, Minoru Nakao, Shuichi Ozawa, Masayuki Kagemoto","doi":"10.5603/rpor.104144","DOIUrl":"https://doi.org/10.5603/rpor.104144","url":null,"abstract":"","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"122-125"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of 3D printing for personalized boluses in radiotherapy: a systematic review.","authors":"Aleksandra Bochyńska, Anna Zawadzka, Paweł Kukołowicz, Mateusz Jacek Spałek","doi":"10.5603/rpor.104014","DOIUrl":"https://doi.org/10.5603/rpor.104014","url":null,"abstract":"<p><p>The goal of this study was to evaluate the current literature covering the topic of 3D-printed radiotherapy boluses in the context of fabrication methods, materials, and clinical outcomes. This systematic review followed the PRISMA 2020 guidelines. Data were extracted for authors, publication details, application type, printing technique and materials, study type, radiation type, reported outcomes and implementation difficulties. The search yielded 161 articles, 52 of which met the inclusion criteria. Publications on 3D printing for customized boluses have increased since 2014, with the most articles from the United States (21%). Most studies (80.8%) focused on manufacturing custom boluses and testing 3D printing materials, whereas 19.2% explored creating molds for boluses. CT scans were the primary method for defining the bolus area (88.6%). The publications included three study types: dosimetric evaluations, evaluations with anthropomorphic phantoms, and clinical case studies. Fused Deposition Modeling (FDM) was the most common printing technique (88.1%), with Polylactic Acid (PLA) being the most frequently used material (57.1%). Challenges included ensuring proper fit, assessing material properties, and managing printing time. The outcomes of this review suggest that 3D printing technology holds significant promise for improving radiotherapy by creating custom-fit boluses. 3D-printed boluses demonstrated notable advantages, such as improved dose distribution, better bolus conformity, and reduced setup times. However, several limitations have been identified, including considerable variability in study designs, making it challenging to draw generalized conclusions. Some studies had small sample sizes or did not clearly report methodological details. Addressing these issues will help to optimize technology's implementation.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"30 1","pages":"100-113"},"PeriodicalIF":1.2,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective, comparative evaluation of an augmented reality tool (Postural Video™) <i>vs</i>. standard SGRT for efficient patient setup.","authors":"Kira Oliver, Nicholas Subick, Torsten Moser","doi":"10.5603/rpor.104011","DOIUrl":"10.5603/rpor.104011","url":null,"abstract":"<p><strong>Background: </strong>Surface guided radiation therapy (SGRT) for patient positioning and motion management during radiation therapy is used on ~40% of US linear accelerators. Postural Video™ (PV), an augmented reality tool for SGRT, is showing a live patient video feed against an outline of the intended treatment position, at patient setup and intrafraction monitoring. A study was performed to assess any potential additional values of SGRT with PV, versus SGRT alone.</p><p><strong>Materials and methods: </strong>Two radiation therapy centers, comparable across patient numbers, case mix, treatment times and staff experience, were selected to compare performance difference in SGRT with/without PV, focused on productivity. Site A used SGRT alone for patient setup, while Site B used SGRT with PV. Both sites were proficient in the use of SGRT prior to the study. 250 treatment delivery fractions per site were analyzed, evaluating average patient setup time, average wait time and frequency of repeated radiographic imaging. A qualitative survey completed information of PV impact on setup quality, access, and efficiency.</p><p><strong>Results: </strong>Average time saving per patient by introducing PV is 28.8% plus additional 60 sec time saving in patient wait time. Repeated radiographic imaging was reduced by 63% (p < 0.05). Qualitative ratings and open comments supported PV being included in standard SGRT.</p><p><strong>Conclusions: </strong>The scope of this work was to evaluate a feature under economic considerations. This data demonstrates an increase in quality, safety, accuracy and efficiency of patient setup with PV, and allows us to make an objective, business-focused assessment of the investment in PV.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 6","pages":"740-745"},"PeriodicalIF":1.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carcinoma lung with cutaneous metastasis: experience from an Indian institute.","authors":"Diptajit Paul, Sheeba Bhardwaj, Abhishek Soni, Ashok Chauhan, Rakesh Dhankhar, Paramjeet Kaur","doi":"10.5603/rpor.103526","DOIUrl":"10.5603/rpor.103526","url":null,"abstract":"<p><strong>Background: </strong>Majority of lung cancer patients are presented with metastatic disease. However, cutaneous metastasis (CM) from lung carcinoma is a rare entity with very few case reports published in the Indian background. Moreover, outcome in these patients is dismal and no standard therapeutic approaches are there. Thus, a long-term analysis from a single institute in this infrequent occurrence holds scientific importance. The purpose of this study was to describe the clinico-demographic profile of patients having CM with lung primary and also to evaluate the survival outcomes in these patients.</p><p><strong>Materials and methods: </strong>This was a retro-prospective study conducted over 5-year time period in an academic institute of India. Records of all histopathologically confirmed lung cancer patients were reviewed and patients having biopsy-proven CM were included in this analysis. Permission from Institutional Ethics Committee and informed consent from all the patients were taken. Data of these patients were collected and analysed using standard statistical software.</p><p><strong>Results: </strong>Total of 25 cases of biopsy-proven CM were found in the stipulated time period. Mean age of patients was 57.6 years with high male predominance. Anterior chest wall was the most common site of skin involvement and squamous cell carcinoma was the most common primary histopathology. Overall, median survival was 4.9 months.</p><p><strong>Conclusion: </strong>Once CM developed, survival of lung carcinoma patients become dismal. Goal of the treatment will be to palliate and to improve quality of life in these patients. Understanding the clinical pattern and demographic profile of these patients will guide a standard treatment approach.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 6","pages":"690-699"},"PeriodicalIF":1.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiotherapy results for <i>de-novo</i> extracranial oligometastatic cancer patients.","authors":"Ipek Pinar Aral, Gonca Altınışık İnan, Suheyla Aytac Arslan, Ali Kerim Aksakal, Huseyin Furkan Ozturk, Yasin Caygın, Havva Beyaz, Muhammet Bülent Akıncı, Yılmaz Tezcan","doi":"10.5603/rpor.103528","DOIUrl":"10.5603/rpor.103528","url":null,"abstract":"<p><strong>Background: </strong>The aim of study was to evaluate the oncological results of stereotactic body radiotherapy (SBRT) in de-novo oligometastatic (dOM) disease.</p><p><strong>Materials and methods: </strong>Patients who underwent SBRT for dOM disease in Radiation Oncology Clinic of <b>XXX</b> Hospitals were analyzed retrospectively. The endpoints of the study were overall survival (OS) and disease free survival (DFS).</p><p><strong>Results: </strong>84 patients with treated between 08.06.2019-15.11.2022 were analyzed. The median follow up was 26 (range 6-219) months. dOM subgroups were as follows: 37 (44.0%) synchronous dOM (sdOM); 31 (37%) metachronous oligorecurrence (mdOR) and 16 (19.0%) metachronous oligoprogression (mdOP). Grade 1 acute side effects (ASE) were observed in only 1 patient and no grade ≥ 2 a ASE were observed. Progression was observed in 45 (53.6%) of the patients. The median DFS was 8 (range 1-32) mo, 1y DFS was 44.5%; 2y DFS was 26.2%. Significantly higher DFS was obtained in mdOR than sdOM and mdOP [p = 0.020; hazard ratio (HR): 1.6; 95% confidence interval (CI): 0.75-3.68%]. The relationship between response assessment after SBRT and DFS was significant (p < 0.001; HR: 4.8; 95% CI: 1.9-12.2). Twenty-nine (34.5%) patients were ex and 55 (65.5%) were alive. 1y OS was 75.6%; 2y OS -61.2%; 3y OS -57.4% and the median OS value has not yet been reached. Lower OS was observed in sdOM compared to mdOP and mdOR (p = 0.035, HR: 0.45; 95% CI: 0.21-0.96). The relationship between response assessment after SBRT and OS was significant (p = 0.017; HR: 6.6; 95% CI: 1.7-25.7).</p><p><strong>Conclusion: </strong>Higher DFS was observed in mdOR patients and lower OS was observed in sdOM patients. SBRT response in dOM patients may be a prognostic factor for DFS and OS.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 6","pages":"667-674"},"PeriodicalIF":1.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A study to compare the efficacy of neoadjuvant chemotherapy in locally advanced human epidermal growth factor receptor 2 overexpressing breast cancer.","authors":"Dharmendra Singh, Pritanjali Singh, Amiy Arnav, Nishit Ranjan, Ashis Ranjan","doi":"10.5603/rpor.104019","DOIUrl":"10.5603/rpor.104019","url":null,"abstract":"<p><strong>Background: </strong>This prospective single institutional study was conducted to compare the efficacy of the two different neoadjuvant chemotherapy (NACT) regimens in human epidermal growth factor receptor 2 (Her2neu) overexpressing non metastatic breast cancer.</p><p><strong>Materials and methods: </strong>Patients randomly assigned into two arms in a 1:1 ratio. Arm A received NACT containing docetaxel, doxorubicin, and cyclophosphamide (TAC) regimen. Arm B received NACT containing docetaxel, carboplatin, and trastuzumab (TCH) regimen. Patients underwent surgical intervention following completion of 6 cycles of NACT. Postoperative histopathological reports were compared in terms of pathological response.</p><p><strong>Results: </strong>122 patients (Arm A = 61; Arm B = 61) analysed. The mean breast tumor size was 7.724 cm and 7.896 cm in Arm A and Arm B, respectively, at diagnosis and clinical staging. After 6 cycles of NACT, the mean breast tumor size in Arm A and Arm B was 3.495 cm and 3.711 cm, respectively. The Arm A and Arm B exhibited 22.9% and 40.9% of pathological complete response (pCR), respectively, with statistically significant difference (p = 0.033). All patients experienced varying degrees of bone marrow suppression. Grade 2 or 3 chemotherapy induced nausea and vomiting was 37.7% and 23% in Arm A and Arm B, respectively, without statistically significant difference (p = 0.076). 14.8% and 4.9% of patients exhibited febrile neutropenia in Arm A and Arm B, respectively, without statistically significant differences (p = 0.067).</p><p><strong>Conclusion: </strong>TCH exhibited greater pCR with tolerable adverse reactions in Her2neu overexpressing breast cancer compared to TAC regimen as NACT. Therefore, TCH regimen should be considered for node positive Her2neu overexpressing breast cancer.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 6","pages":"764-775"},"PeriodicalIF":1.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET/CT-based dose-escalated definitive radiotherapy in cervical cancer: a single-institution series.","authors":"Samir A Hanna, Alice R N S Silva, Leticia Hernandes de Brito, Gabriela Silva Moreira de Siqueira, Tatiana Midori Martins Teles Alves, Daniela de Freitas, Rudinei Linck, José Carlos Sadalla, Sergio Mancini Nicolau, Carlos Buchpiguel, Jesus Paula Carvalho","doi":"10.5603/rpor.104018","DOIUrl":"10.5603/rpor.104018","url":null,"abstract":"<p><strong>Background: </strong>The objective was to evaluate clinical outcomes and toxicity of patients with cervical cancer treated by radiotherapy with dose escalation in involved lymph nodes based on positron emission tomography/computed tomography (PET/CT) staging.</p><p><strong>Materials and methods: </strong>Retrospective cohort study involving locally advanced cervical neoplasms treated with definitive radiotherapy. Volumetric modulated arc therapy (VMAT), image-guided radiotherapy (IGRT), and registration of PET/CT were employed in all. Involved lymph nodes were given higher doses simultaneously.</p><p><strong>Results: </strong>Between February 2012 and September 2023, there were 37 patients, with median age of 48 (range 27-91) years. Almost 70% were stages III/IVA. Two-thirds were given retroperitoneal irradiation. The mean delivered doses to primary tumor and to involved lymph nodes were, respectively, 52.5 Gy, and 62.5 Gy. The 10-year rates of overall survival, event-free survival, local-recurrence-free survival, and metastasis-free survival were, respectively, 76%, 50%, 91%, and 82%. There were 13 and 2 cases of gastrointestinal toxicity grades II and III, respectively. Grades II and III of genitourinary toxicity were seen respectively in 7 and 3 patients. On univariate analysis, age was related to local recurrence-free survival (LRFS); standard uptake values (SUV) was related to event-free survival (EFS); lymph node dose was related to overall survival (OS), and EFS; primary tumor dose was directly related to EFS, albeit inversely to the likelihood of grade > II gastrointestinal toxicity. Retroperitoneal irradiation improved LRFS, and rates of grade > II gastrointestinal toxicity. On multivariate analysis, SUV remained an independent predictor of EFS; lymph node dose was an independent predictor of OS, and age was an independent predictor of lymph node recurrence.</p><p><strong>Conclusion: </strong>Dose escalation radiotherapy (RT) based on PET/CT for cervical cancer may be feasible and safe. Further robust study results are needed.</p>","PeriodicalId":47283,"journal":{"name":"Reports of Practical Oncology and Radiotherapy","volume":"29 6","pages":"754-763"},"PeriodicalIF":1.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}